Lymphoma

The allogeneic CAR-T cell therapy is in development for relapsed or refractory large B cell lymphoma and relapsed or refractory B cell non-Hodgkin lymphoma.

Olutasidenib (Rezlidhia) is indicated for adult patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation detected by an FDA-approved test.

An experimental drug could help scientists understand the development of mantle cell lymphoma and potentially increase overall survival.

Zanubrutinib expressed better cardiac safety measures, higher progression-free survival, and lower discontinuation rates in the ALPINE trial compared with compared ibrutinib.

Agency’s action date is May 21, 2023, for the first subcutaneous bispecific antibody approved for the treatment of large B-cell lymphoma.

FDA approves brentuximab vedotin for the treatment of patients aged 2 years and older with previously untreated, high-risk classical Hodgkin lymphoma, in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.

Study shows combining brentuximab vedotin with the standard chemotherapy regimen reduced the risk of relapse in children with high-risk Hodgkin lymphoma by 10%.

In the inpatient acute care setting, oncology pharmacists maximize return on investments of oncology products, produce optimal outcomes, and ensure that quality of care is consistent and safe.

Epcoritamab is an investigational subcutaneous bispecific antibody being investigated for the treatment of adult patients with relapsed/refractory large B-cell lymphoma.

Research suggests that positron emission tomography scans are effective at detecting early and late Hodgkin’s lymphoma, and the results could help manage and reduce toxicity from current chemotherapies.

Jeremy Graff, chief scientific officer at IMV, discusses why the development of viable cancer vaccines is a bit more slow-going in comparison to the fast-paced development of COVID-19 vaccines during the pandemic.

Omidubicel is a stem cell-based product that utilizes nicotinamide to inhibit differentiation and to increase the migration, bone marrow homing, and engraftment efficiency of hematopoietic progenitor cells.

Yvonne Chen, PhD, discusses some of the strategies that researchers are using to improve T-cell effectiveness and overcome immunosuppression in CAR T-cell therapy.

Two recent clinical trials highlight the novel therapy options available to patients in the upfront and relapsed settings.

Mosunetuzumab showed promising results in complete response rate in patients with follicular lymphoma.

Study results show that the frequency of adverse events decreased after the patients transitioned from combination therapy to monotherapy.

New research has shown significant promise for the use of CAR T-cell therapies in solid tumors.

Combination treatment with ibrutinib found to increase median progression-free survival by 2.3 years compared to the placebo.

This study highlights one benefit of the integrated health system specialty pharmacy model for patients who are prescribed acalabrutinib.

Management of marginal zone lymphoma was impacted by the COVID-19 pandemic because some treatment options can reduce B-cell-produced antibodies.

NVG-111 is a humanized, tandem single-chain variable fragment ROR1 x CD3 BiTE being evaluated in relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.

The biosimilar is expected to be launched as a prefilled syringe in early 2023.

Test can evaluate whether a patient with lymphoma will respond to CAR T-cell therapy, which could lead to better and longer lasting treatment options.

Pemigatinib is the first targeted therapy to gain FDA approval for the treatment of adult patients with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.

Risk factors associated with declining health-related quality of life for adult survivors of childhood cancer, such as physical inactivity and chronic health conditions, should be targets of surveillance and intervention.